Brief Report: Relationship Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease in Persons With HIV.
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
01 08 2020
01 08 2020
Historique:
pubmed:
3
4
2020
medline:
17
2
2021
entrez:
3
4
2020
Statut:
ppublish
Résumé
Nonalcoholic fatty liver disease (NAFLD) and HIV are independently associated with cardiovascular disease (CVD). However, the factors associated with NAFLD in persons living with HIV (PWH) and whether CVD is more frequent in PWH with NAFLD are currently unknown. From the Partners HealthCare Research Patient Data Registry, we identified PWH with and without NAFLD between 2010 and 2017. NAFLD was defined using validated histological or radiographic criteria. CVD was defined by an ICD-9 diagnosis of coronary artery disease, myocardial infarction, coronary revascularization, peripheral vascular disease, heart failure, transient ischemic attack, or stroke and was confirmed by clinician review. Multivariable logistic regression was performed to examine the relationship between NAFLD and CVD. Compared with PWH without NAFLD (n = 135), PWH with NAFLD (n = 97) had higher body mass index and more frequently had hypertension, obstructive sleep apnea, diabetes mellitus, dyslipidemia, coronary artery disease, and CVD (P < 0.01 for all). PWH with NAFLD were also more likely to have CD4 T-cell counts (CD4) <200 cells/mm. In multivariable models, the presence of NAFLD was significantly associated with CVD (adjusted odds ratio 3.08, 95% confidence interval: 1.37 to 6.94) and CD4 <200 cells/mm (adjusted odds ratio 4.49, 95% confidence interval: 1.74 to 11.55). In PWH, CVD was independently associated with prevalent NAFLD after controlling for traditional CVD risk factors. NAFLD was also associated with CD4 <200 cells/mm, suggesting that immune dysfunction may be related to NAFLD. Both CVD and low CD4 count as risk factors for NAFLD require prospective evaluation.
Sections du résumé
BACKGROUND
Nonalcoholic fatty liver disease (NAFLD) and HIV are independently associated with cardiovascular disease (CVD). However, the factors associated with NAFLD in persons living with HIV (PWH) and whether CVD is more frequent in PWH with NAFLD are currently unknown.
METHODS
From the Partners HealthCare Research Patient Data Registry, we identified PWH with and without NAFLD between 2010 and 2017. NAFLD was defined using validated histological or radiographic criteria. CVD was defined by an ICD-9 diagnosis of coronary artery disease, myocardial infarction, coronary revascularization, peripheral vascular disease, heart failure, transient ischemic attack, or stroke and was confirmed by clinician review. Multivariable logistic regression was performed to examine the relationship between NAFLD and CVD.
RESULTS
Compared with PWH without NAFLD (n = 135), PWH with NAFLD (n = 97) had higher body mass index and more frequently had hypertension, obstructive sleep apnea, diabetes mellitus, dyslipidemia, coronary artery disease, and CVD (P < 0.01 for all). PWH with NAFLD were also more likely to have CD4 T-cell counts (CD4) <200 cells/mm. In multivariable models, the presence of NAFLD was significantly associated with CVD (adjusted odds ratio 3.08, 95% confidence interval: 1.37 to 6.94) and CD4 <200 cells/mm (adjusted odds ratio 4.49, 95% confidence interval: 1.74 to 11.55).
CONCLUSION
In PWH, CVD was independently associated with prevalent NAFLD after controlling for traditional CVD risk factors. NAFLD was also associated with CD4 <200 cells/mm, suggesting that immune dysfunction may be related to NAFLD. Both CVD and low CD4 count as risk factors for NAFLD require prospective evaluation.
Identifiants
pubmed: 32235172
doi: 10.1097/QAI.0000000000002359
pii: 00126334-202008010-00010
pmc: PMC10462389
mid: NIHMS1899651
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
400-404Subventions
Organisme : NIDDK NIH HHS
ID : K23 DK122104
Pays : United States
Références
Liver Int. 2012 Jul;32(6):911-8
pubmed: 22672642
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
AIDS. 2017 Jul 17;31(11):1621-1632
pubmed: 28398960
J Clin Transl Hepatol. 2017 Sep 28;5(3):261-271
pubmed: 28936407
World J Hepatol. 2018 Aug 27;10(8):530-542
pubmed: 30190781
HIV Med. 2011 Sep;12(8):463-71
pubmed: 21251186
Clin Infect Dis. 2008 Jul 15;47(2):250-7
pubmed: 18532884
J Acquir Immune Defic Syndr. 2016 Aug 1;72(4):437-43
pubmed: 26990826
Gastroenterology. 2016 Jun;150(8):1778-85
pubmed: 26980624
Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):666-75
pubmed: 24061203
Am J Gastroenterol. 2014 May;109(5):695-704
pubmed: 24642579
Radiology. 2011 Mar;258(3):760-6
pubmed: 21212369
Aliment Pharmacol Ther. 2016 Aug;44(4):411-21
pubmed: 27301337
J Pediatr Gastroenterol Nutr. 2011 Aug;53(2):190-5
pubmed: 21788761
Mediators Inflamm. 2018 Sep 27;2018:6238978
pubmed: 30363715
AIDS. 2002 Nov 8;16(16):2183-93
pubmed: 12409740
Expert Rev Gastroenterol Hepatol. 2019 Jun;13(6):531-540
pubmed: 30905208
BMJ Open. 2014 Mar 13;4(3):e004088
pubmed: 24625638